Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline growth to strengthen for the rest of FY25, the analyst tells investors in a research note. The firm adds that robust sales of GLP-1 weight-loss products, along with higher sales of specialty and oncology drugs, are driving Cencora’s strong performance, and Argus is boosting its FY25 EPS view by 45c to $15.45 and its FY26 view by 35c to $16.75.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Resilient Growth and Stable Outlook: A Buy Rating by Steven Valiquette
- Cencora Earnings Call: Strong Start Amid Challenges
- Cencora expands drug shortages mitigation program
- Cencora price target raised to $307 from $305 at Baird
- Cencora’s Strong Performance and Growth Potential Drive Buy Rating with Increased EPS Guidance
Questions or Comments about the article? Write to editor@tipranks.com